Minimal residual disease in acute lymphoblastic leukemia: optimal methods and clinical relevance, pitfalls and recent approaches

Medical Oncology

Volumn 31, Issue 11, 2014, Pages 1-9

  Salari, Fatemeh ^a   Shahjahani, Mohammad ^a   Shahrabi, Saeid ^b   Saki, Najmaldin ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SEMNAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute lymphoblastic leukemia; Methods; Minimal residual disease

Indexed keywords

T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR RUNX1; GENETIC MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; DISEASE MARKER; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; REVIEW; SYMPTOM; ANIMAL; GENETIC MARKER; GENETICS; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ANIMALS; GENETIC MARKERS; HUMANS; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84919928629     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0266-3     Document Type: Review

References (87)

1. Nyvold C, Madsen HO, Ryder LP, Seyfarth J, Svejgaard A, Clausen N, et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood. 2002;99(4):1253–8.
2. Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol. 2003;121(6):823–38.
3. Szczepański T, van der Velden VH, van Dongen JJ. Flow-cytometric immunophenotyping of normal and malignant lymphocytes. Clin Chem Lab Med. 2006;44(7):775–96.
4. Cazzaniga G, Biondi A. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica. 2005;90(3):382–90.
5. Hoelzer D, Gokbuget N, Ottmann O, Pui C-H, Relling MV, Appelbaum FR, et al. Acute lymphoblastic leukemia. Hematology. 2002;2002(1):162–92.
6. Bunin N, Johnston DA, Roberts WM, Ouspenskaia MV, Papusha VZ, Brandt MA, et al. Residual leukaemia after bone marrow transplant in children with acute lymphoblastic leukaemia after first haematological relapse or with poor initial presenting features. Br J Haematol. 2003;120(4):711–5.
7. Cazzaniga G, Gaipa G, Rossi V, Biondi A. Minimal residual disease as a surrogate marker for risk assignment to ALL patients. Rev Clin Exp Hematol. 2003;7(3):292–323.
8. Hoelzer D. Monitoring and managing minimal residual disease in acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book. 2013;33:290–3.
9. Van der Velden V, Joosten S, Willemse M, Van Wering E, Lankester A, Van Dongen J, et al. Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. Leukemia. 2001;15(9):1485.
10. Bader P, Hancock J, Kreyenberg H, Goulde N, Niethammer D, Oakhill A, et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia (08876924). 2002;16(9):1668–72.
11. Lankester AC, Bierings M, Van Wering E, Wijkhuijs A, de Weger R, Wijnen J, et al. Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia. 2010;24(8):1462–9.
12. Yeoh AEJ, Ariffin H, Chai ELL, Kwok CSN, Chan YH, Ponnudurai K, et al. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia–Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol. 2012;30(19):2384–92.
13. Van der Velden V, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, Van Dongen J. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003;17(6):1013–34.
14. van Dongen J. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257–317.
15. Lankester A, Bierings M, van Wering E, Wijkhuijs A, de Weger R, Wijnen J, et al. Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia (08876924). 2010;24(8):1462–9.
16. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22(4):771–82.
17. Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113(18):4153–62.
18. Brüggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann O, et al. Standardized MRD quantification in European ALL trials: proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18–20 September 2008. Leukemia. 2010;24(3):521–35.
19. Caye A, Beldjord K, Mass-Malo K, Drunat S, Soulier J, Gandemer V, et al. Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2013;98(4):597–601.
20. Van der Velden V, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer E, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21(4):604–11.
21. Dworzak MN, Gaipa G, Ratei R, Veltroni M, Schumich A, Maglia O, et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: multicentric assessment is feasible. Cytom Part B Clin Cytom. 2008;74(6):331–40.
22. Brüggemann M, Droese J, Bolz I, Lüth P, Pott C, Von Neuhoff N, et al. Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. Leukemia (08876924). 2000;14(8):1419–25.
23. Szczepański T. WillemseM, Van Wering E, Van Weerden J, Kamps W, Van Dongen J. Precursor-B-ALL with D H-J H gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14. Leukemia (08876924). 2001;15(9):1415–23.
24. Peham M, Panzer S, Fasching K, Haas OA, Fischer S, Marschalek R, et al. Low frequency of clonotypic Ig and T‐cell receptor gene rearrangements in t (4; 11) infant acute lymphoblastic leukaemia and its implication for the detection of minimal residual disease. Br J Haematol. 2002;117(2):315–21.
25. Szczepański T, Flohr T, van der Velden VH, Bartram CR, van Dongen JJ. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2002;15(1):37–57.
26. Van der Velden V, Willemse M, Van der Schoot C, Hählen K, Van Wering E, Van Dongen J. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targetsfor detection of minimal residual disease by real-time quantitative PCR. Leukemia (08876924). 2002;16(5):928–36.
27. Beishuizen A, Verhoeven MA, Mol EJ, van Dongen JJ. Detection of immunoglobulin kappa light-chain gene rearrangement patterns by Southern blot analysis. Leukemia. 1994; 8(12):2228–36; discussion 37–9.
28. Van der Velden V, Wijkhujis J, Jacobs D, Van Wering E, Van Dongen J. T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia (08876924). 2002;16(7):1372–80.
29. Meleshko A, Lipay N, Stasevich I, Potapnev M. Rearrangements of IgH, TCRD and TCRG genes as clonality marker of childhood acute lymphoblastic leukemia. Exp Oncol. 2005;27(4):319–24.
30. Szczepański T, Langerak A, Willemse M, Wolvers-Tettero I, Van Wering E, Van Dongen J. T cell receptor gamma (TCRG) gene rearrangements in T cell acute lymphoblastic leukemia reflect ‘end-stage’recombinations: implications for minimal residual disease monitoring. Leukemia (08876924). 2000;14(7):1208–14.
31. Moreau E, Langerak A, van Gastel-Mol E, Wolvers-Tettero I, Zhan M, Zhou Q, et al. Easy detection of all T cell receptor gamma (TCRG) gene rearrangements by Southern blot analysis: recommendations for optimal results. Leukemia (08876924). 1999;13(10):1620–6.
32. Van Dongen J, Langerak A, Brüggemann M, Evans P, Hummel M, Lavender F, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17(12):2257–317.
33. Krampera M, Perbellini O, Vincenzi C, Zampieri F, Pasini A, Scupoli MT, et al. Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. Haematologica. 2006;91(8):1109–12.
34. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood. 2008;111(12):5477–85.
35. Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol. 2009;27(31):5168–74.
36. Dworzak M. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002;99:1952–8.
37. Lucio P, Gaipa G, Van Lochem E, Van Wering E, Porwit-MacDonald A, Faria T, et al. BIOMED-1 concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. Leukemia (08876924). 2001;15(8):1185–92.
38. Dworzak M, Fröschl G, Printz D, De Zen L, Gaipa G, Ratei R, et al. CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. Leukemia. 2004;18(4):703–8.
39. Dworzak M, Fritsch G, Fleischer C, Printz D, Fröschl G, Buchinger P, et al. Comparative phenotype mapping of normal vs. malignant pediatric B-lymphopoiesis unveils leukemia-associated aberrations. Exp Hematol. 1998;26(4):305–13.
40. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry. 1999;38(4):139–52.
41. Weir E, Cowan K, LeBeau P, Borowitz M. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Leukemia (08876924). 1999;13(4):558–67.
42. Veltroni M, De Zen L, Sanzari MC, Maglia O, Dworzak MN, Ratei R, et al. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia. Haematologica. 2003;88(11):1245–52.
43. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96(8):2691–6.
44. Assumpcao JG, Paula FDF, Xavier SG, Murao M, Aguirre Neto JCd, Dutra AP, et al. Gene rearrangement study for minimal residual disease monitoring in children with acute lymphocytic leukemia. Revist Brasileira De Hematol E Hemoter. 2013;35(5):337–42.
45. Dworzak MN, Panzer-Grümayer ER. Flow cytometric detection of minimal residual disease in acute lymphoblastic leukemia. Leuk Lymphoma. 2003;44(9):1445–55.
46. De Haas V, Verhagen O, von dem Borne A, Kroes W, Van Den Berg H, Van Der Schoot C. Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy. Leukemia. 2001;15(1):134–40.
47. Coustan-Smith E, Sancho J, Behm FG, Hancock ML, Razzouk BI, Ribeiro RC, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood. 2002;100(1):52–8.
48. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206–14.
49. Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011;118(8):2077–84.
50. Zhou J, Goldwasser MA, Li A, Dahlberg SE, Neuberg D, Wang H, et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood. 2007;110(5):1607–11.
51. Coustan-Smith E, Sancho J, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK, et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood. 2002;100(7):2399–402.
52. Borowitz MJ, Pullen DJ, Winick N, Martin PL, Bowman WP, Camitta B. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children’s oncology group. Cytom Part B Clin Cytom. 2005;68(1):18–24.
53. Gaipa G, Basso G, Maglia O, Leoni V, Faini A, Cazzaniga G, et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia. 2005;19(1):49–56.
54. Pui C-H, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166–78.
55. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood. 2008 Jun 15;111(12):5477-85.
56. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, Van Der Velden V, Fischer S, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22(4):771–82.
57. van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. The Lancet. 1998;352(9142):1731–8.
58. Ryan J, Quinn F, Meunier A, Boublikova L, Crampe M, Tewari P, et al. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches. Br J Haematol. 2009;144(1):107–15.
59. Basso G, Veltroni M, Grazia Valsecchi M, Dworzak MN, Ratei R, D Silvestri, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol. 2009;27(31):5168–74.
60. Guggemos A, Eckert C, Szczepanski T, Hanel C, Taube T, van der Velden V, et al. Assessment of clonal stability of minimal residual disease targets between 1st and 2nd relapse of childhood precursor B-cell acute lymphoblastic leukemia. Haematologica. 2003;88(7):737–46.
61. Gawad C, Pepin F, Carlton VE, Klinger M, Logan AC, Miklos DB, et al. Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. Blood. 2012;120(22):4407–17.
62. Nyvold C. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and anexcellent outcome. Blood. 2002;99:1253–8.
63. Cazzaniga G, Biondi A. Molecular monitoring of minimal residual disease. Treatment of acute leukemias. Berlin: Springer; 2003. p. 537–47.
64. Borowitz M, Pullen D, Winick N, Martin P, Bowman W, Camitta B. Comparisonof diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children’s oncology group. Cytom Part B Clin Cytom. 2005;68(1):18–24.
65. Dworzak M, Fritsch G, Fleischer C, Printz D, Fröschl G, Buchinger P, et al. Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow. Leukemia (08876924). 1997;11(8):1266–73.
66. McKenna RW, Washington LT, Aquino DB, Picker LJ, Kroft SH. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood. 2001;98(8):2498–507.
67. Rhein P, Mitlohner R, Basso G, Gaipa G, Dworzak MN, Kirschner-Schwabe R, et al. CD11b is a therapy resistance-and minimal residual disease—specific marker in precursor B-cell acute lymphoblastic leukemia. Blood. 2010;115(18):3763–71.
68. DiGiuseppe JA, Fuller SG, Borowitz MJ. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: Potential usefulness in minimal residual disease detection. Cytom Part B Clin Cytom. 2009;76(2):150–5.
69. Muzzafar T, Medeiros LJ, Wang SA, Brahmandam A, Thomas DA, Jorgensen JL. Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia utility in detection of minimal residual disease by flow cytometry. Am J Clin Pathol. 2009;132(5):692–8.
70. Neale G, Coustan-Smith E, Stow P, Pan Q, Chen X, Pui C, et al. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 2004;18(5):934–8.
71. Van der Velden V, Szczepanski T, Wijkhuijs J, Hart P, Hoogeveen P, Hop W, et al. Age-related patterns of immunoglobulin and T-cell receptor gene rearrangements in precursor-B-ALL: implications for detection of minimal residual disease. Leukemia. 2003;17(9):1834–44.
72. Malec M, Van der Velden V, Björklund E, Wijkhuijs J, Söderhäll S, Mazur J, et al. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping. Leukemia. 2004;18(10):1630–6.
73. Van der Velden V, Panzer-Grümayer E, Cazzaniga G, Flohr T, Sutton R, Schrauder A, et al. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia. 2007;21(4):706–13.
74. Aricò M, Valsecchi MG, Rizzari C, Barisone E, Biondi A, Casale F, et al. Long-term results of the AIEOP-ALL-95 trial for childhood acute lymphoblastic leukemia: insight on the prognostic value of DNA index in the framework of berlin-frankfurt-muenster-based chemotherapy. J Clin Oncol. 2008;26(2):283–9.
75. Irving J, Jesson J, Virgo P, Case M, Minto L, Eyre L, et al. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting. Haematologica. 2009;94(6):870–4.
76. Klein O, Schmidt C, Knights A, Davis ID, Chen W, Cebon J. Melanoma vaccines: developments over the past 10 years. Expert Rev Vaccines. 2011;10(6):853–73.
77. Van Dongen J, Macintyre E, Gabert J, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia (08876924). 1999;13(12):1901–28.
78. Luria D, Rosenthal E, Steinberg D, Kodman Y, Safanaiev M, Amariglio N, et al. Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia. Cytom Part B Clin Cytom. 2010;78(6):365–71.
79. Robillard N, Cavé H, Méchinaud F, Guidal C, Garnache-Ottou F, Rohrlich PS, et al. Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia. Haematologica. 2005;90(11):1516–23.
80. Gaipa G, Cazzaniga G, Valsecchi MG, Panzer-Grümayer R, Buldini B, Silvestri D, et al. Time point-dependent concordance of flow cytometry and RQ-PCR in minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica. 2012: Haematologica. 2011.060426
81. Van der Velden V, Wijkhuijs J, Van Dongen J. Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring. Leukemia. 2008;22(3):641–4.
82. Campana D, Neale G, Coustan-Smith E, Pui C. Detection of minimal residual disease in acute lymphoblastic leukemia: the St Jude experience. Leukemia. 2001;15(2):278–9.
83. Poopak B, Saki N, Purfatholah AA, Najmabadi H, Mortazavi Y, Arzanian MT, et al. Pattern of immunoglobulin and T-cell receptor-δ/γ gene rearrangements in Iranian children with B-precursor acute lymphoblastic leukemia. Hematology. 2013.
84. Germano GD, Del Giudice L, Palatron S, Giarin E, Cazzaniga G, Biondi A, et al. Clonality profile in relapsed precursor-B-ALL children by genescan and sequencing analyses. Consequences on minimal residual disease monitoring. Leukemia. 2003;17(8):1573–82.
85. Faham M, Zheng J, Moorhead M, Carlton VE, Stow P, Coustan-Smith E, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2012;120(26):5173–80.
86. Boyd SD, Marshall EL, Merker JD, Maniar JM, Zhang LN, Sahaf B, et al. Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. Sci Transl Med. 2009;1(12):12ra23.
87. Orfao A, Schmitz G, Brando B, Ruiz-Arguelles A, Basso G, Braylan R, et al. Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions. Clin Chem. 1999;45(10):1709.